X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE CIPLA SUVEN LIFE/
CIPLA
 
P/E (TTM) x 19.2 44.6 43.0% View Chart
P/BV x 3.6 3.8 93.0% View Chart
Dividend Yield % 1.1 0.3 313.7%  

Financials

 SUVEN LIFE   CIPLA
EQUITY SHARE DATA
    SUVEN LIFE
Mar-16
CIPLA
Mar-17
SUVEN LIFE/
CIPLA
5-Yr Chart
Click to enlarge
High Rs339622 54.4%   
Low Rs144458 31.5%   
Sales per share (Unadj.) Rs39.2181.9 21.6%  
Earnings per share (Unadj.) Rs7.512.9 58.0%  
Cash flow per share (Unadj.) Rs8.829.3 29.9%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.4 223.7%  
Book value per share (Unadj.) Rs49.0155.7 31.5%  
Shares outstanding (eoy) m127.28804.51 15.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.23.0 207.1%   
Avg P/E ratio x32.442.0 77.1%  
P/CF ratio (eoy) x27.518.4 149.3%  
Price / Book Value ratio x4.93.5 142.0%  
Dividend payout %26.815.5 172.5%   
Avg Mkt Cap Rs m30,732434,516 7.1%   
No. of employees `0001.023.0 4.1%   
Total wages/salary Rs m41626,338 1.6%   
Avg. sales/employee Rs Th5,236.16,349.1 82.5%   
Avg. wages/employee Rs Th436.51,143.0 38.2%   
Avg. net profit/employee Rs Th995.5449.3 221.5%   
INCOME DATA
Net Sales Rs m4,995146,302 3.4%  
Other income Rs m1942,287 8.5%   
Total revenues Rs m5,189148,589 3.5%   
Gross profit Rs m1,23324,758 5.0%  
Depreciation Rs m16713,229 1.3%   
Interest Rs m541,594 3.4%   
Profit before tax Rs m1,20512,222 9.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2551,798 14.2%   
Profit after tax Rs m95010,354 9.2%  
Gross profit margin %24.716.9 145.8%  
Effective tax rate %21.214.7 143.9%   
Net profit margin %19.07.1 268.6%  
BALANCE SHEET DATA
Current assets Rs m4,98687,370 5.7%   
Current liabilities Rs m1,04233,081 3.2%   
Net working cap to sales %79.037.1 212.8%  
Current ratio x4.82.6 181.1%  
Inventory Days Days6187 70.1%  
Debtors Days Days3962 62.8%  
Net fixed assets Rs m3,126111,567 2.8%   
Share capital Rs m1271,609 7.9%   
"Free" reserves Rs m3,717123,645 3.0%   
Net worth Rs m6,236125,254 5.0%   
Long term debt Rs m43236,454 1.2%   
Total assets Rs m8,079209,532 3.9%  
Interest coverage x23.28.7 268.0%   
Debt to equity ratio x0.10.3 23.8%  
Sales to assets ratio x0.60.7 88.5%   
Return on assets %12.45.7 217.9%  
Return on equity %15.28.3 184.2%  
Return on capital %18.98.5 222.1%  
Exports to sales %87.534.2 255.8%   
Imports to sales %12.28.3 146.6%   
Exports (fob) Rs m4,37150,050 8.7%   
Imports (cif) Rs m61112,203 5.0%   
Fx inflow Rs m4,66651,066 9.1%   
Fx outflow Rs m94217,678 5.3%   
Net fx Rs m3,72433,388 11.2%   
CASH FLOW
From Operations Rs m92223,824 3.9%  
From Investments Rs m-619-13,127 4.7%  
From Financial Activity Rs m-698-13,239 5.3%  
Net Cashflow Rs m-396-2,478 16.0%  

Share Holding

Indian Promoters % 63.4 16.0 396.3%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.0 12.2 -  
FIIs % 0.0 23.7 -  
ADR/GDR % 0.0 1.1 -  
Free float % 36.5 26.2 139.3%  
Shareholders   37,287 161,166 23.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALEMBIC PHARMA  AJANTA PHARMA  

Compare SUVEN LIFE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


Feb 23, 2018 (Close)

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUVEN LIFE WITH

MARKET STATS